All analyses
AI analysis

Commercial Development Co. Plc: research report

UndervaluedbullishNov 17, 2026

Evidence points bullish: CDC scores 91 of 100 for value across the CSE and has substantial short-term asset cover. The contrary is that September net profit fell 11.5% year-on-year.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • CDC scores 91 of 100 on price against book value, earnings and dividends, placing it in the CSE's Undervalued band.
  • Its P/B of 0.76 is below the property and construction peer median of 1.21, while the current ratio is 11.21 times.

Against this. September-quarter net profit fell 11.5% year-on-year as gross margin dropped to the weakest September result in eight records.

Operating margin
43.4%sector 12.2%
from 49.9% a year earlier
Net margin
36.5%sector 7.9%
from 41.1% a year earlier, revenue -0.2%
Return on equity
8.5%
twelve months to Sep 30, 2026, unaudited
P/E
9.0sector 10.7
earnings Rs 32.32 per share, year to Sep 2026
P/B
0.76sector 1.15
book Rs 382.69 per share
Dividend yield
3.77%sector 2.04%
34.0% of earnings paid out

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 17, 2026. Sector figures are the median of 32 listed companies in the same sector.

Overview

Commercial Development provides property management, premises rental, facilities, staffing, fleet and technical services, principally to Commercial Bank of Ceylon and other group clients. The latest quarter showed a contraction in earnings despite broadly steady revenue, making margin preservation and the relationship with its principal customer central to the case.

Price performance

At LKR 292 on 17 November 2026, the share had fallen 5.0% over three months while the ASPI gained 1.0%; over six months it fell 9.7% against a 2.7% ASPI decline. The relative weakness has therefore been more pronounced than the index move over these windows.

The price sits 54.1% through its 52-week range. Sixty-day annualised volatility was 61.3%, above its own one-year 45.6% norm, while recent volume was 94.3% above the preceding 60-day pace, showing that trading has become more active than this share's normal pattern.

The record shows two falls of 15% or more in three years, the deepest 21%, which has not yet recovered. Liquidity is exceptionally limited: median daily turnover was LKR 13,156, and a LKR 1 million order is more than everything that trades on a typical day (7601% of it).

Valuation

On the twelve months to September 2026, the P/E is 9.0 times, meaning LKR 9 is paid for each LKR 1 of trailing profit, below the sector median of 10.8 times. The P/B is 0.76 times, or 76 cents for each rupee of net assets, versus a sector median of 1.21; it sits at the cheaper end of the peer group, with a 20th-percentile P/B among 31 peers.

The peer comparison conflicts with CDC's own record: its P/B is “more expensive than 81% of days since February 2012”. At this price, 22.5% of trailing EPS came from the September quarter; had that quarter earned its year-ago net margin, the P/E would be 8.8 times rather than 9.0 times. The 3.8% dividend yield is above the 3.3% sector median, but the LKR 4 recorded for FY2026 so far is below the LKR 7 paid in each of FY2024 and FY2025; the latest year may not yet be complete.

News and sentiment

Direct coverage is thin, with one material article in the past 90 days, classified positive because it reported a cash dividend. The 6 November report covered the LKR 4 dividend whose ex-date was 17 November and whose payment is due on 7 December 2026.

The dividend is already ex, so a buyer on 17 November does not receive it. There is no other material company-specific news in the supplied coverage.

Financials

September-quarter revenue was effectively flat year-on-year, down 0.2% to LKR 242.9 million, but net profit fell 11.5% to LKR 88.6 million. Gross margin was 31.8% versus 57.2% a year earlier, operating margin was 43.4% versus 49.9%, and net margin was 36.5% versus 41.1%. The gross margin was the worst of eight comparable September quarters, while operating margin ranked among the weakest, at seventh of eight.

Operating profit fell 13.3%, so the profit attributable to each share was supported by a smaller operating result than a year earlier. Below operating profit, finance costs, tax, associates and FX collectively reduced profit by LKR 16.8 million, compared with LKR 21.5 million a year earlier, partly softening the operating decline.

Equity rose to LKR 4.6 billion from LKR 4.3 billion a year earlier. Shares outstanding remained 12 million in both periods, so the weaker quarterly earnings are not a mechanical consequence of a changed share count.

Risks

The principal business risk is customer concentration: CDC's property and support-service mandate is primarily directed to Commercial Bank of Ceylon, leaving earnings dependent on one principal relationship. The September gross margin of 31.8% was the weakest comparable September result in eight observations, showing that the latest profit decline was not solely a revenue issue.

Cash conversion is the next financial check. In the latest audited year, operating cash flow was 0.37 times operating profit, meaning only 37 cents of operating cash arrived for each rupee of operating profit. This matters because reported profit is less reassuring when it is not matched by cash collection.

Liquidity and interest obligations appear less pressing on the available annual data. The current ratio was 11.21 times, meaning assets expected to turn into cash within a year, including unsold goods and customer receivables, were more than eleven times bills due within that year. Interest cover was 43.0 times, meaning operating profit covered the interest bill many times over.

Outlook

As at 17 November 2026, the next material company event is the audited year-end filing for 31 December 2026, expected between 28 April and 3 June 2027. It will show whether the September margin compression persisted through the year and whether operating cash conversion improved.

The property and construction backdrop includes higher planned public capital spending and earlier tendering procedures, but the supplied data does not establish a direct revenue or earnings link to CDC's bank-focused facilities business. The current data therefore cannot determine the extent to which wider construction activity changes CDC's earnings base.

About this report. Generated on Nov 17, 2026 from market data up to Nov 17, 2026, 1 material news articles over 90 days and financials to Sep 30, 2026, and scored 91 of 100 on value (undervalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports